| Date Filed | Type | Description |
| 09/26/2023 |
8-K/A
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/25/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 08/25/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 08/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/24/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 08/23/2023 |
SC 13D
| Camac Fund, LP reports a 4.3% stake in Forte Biosciences, Inc. |
| 08/17/2023 |
PRRN14A
| Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise: |
| 08/15/2023 |
SC 13D/A
| Wagner Paul A. reports a 5.2% stake in Forte Biosciences, Inc. |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 8.2% stake in Forte Biosciences, Inc. |
| 08/10/2023 |
SC 13G
| Farallon Capital Partners, L.P. reports a 9.9% stake in Forte Biosciences, Inc. |
| 08/10/2023 |
SC 13D/A
| ATG Fund II LLC reports a 4% stake in Forte Biosciences, Inc. |
| 08/09/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/04/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/03/2023 |
SC 13D/A
| Camac Fund, LP reports a 3.6% stake in Forte Biosciences Inc. |
| 08/02/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
SC 13D/A
| Funicular Funds, LP reports a 9.6% stake in Forte Biosciences, Inc. |
| 07/05/2023 |
SC 13D/A
| Camac Fund, LP reports a 8.6% stake in Forte Biosciences Inc. |
| 05/25/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 05/25/2023 |
SC 13D/A
| Camac Fund, LP reports a 8.6% stake in Forte Biosciences Inc. |
| 03/31/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/31/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/21/2023 |
SC 13D/A
| Camac Fund, LP reports a 8.6% stake in Forte Biosciences Inc. |
| 02/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 01/12/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 09/28/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/22/2022 |
SC 13D/A
| Funicular Funds, LP reports a 10% stake in Forte Biosciences, Inc. |
| 09/12/2022 |
SC 13G/A
| MORGAN STANLEY reports a 1.1% stake in Forte Biosciences, Inc. |
| 08/24/2022 |
SC 13D/A
| Funicular Funds, LP reports a 8% stake in Forte Biosciences, Inc. |
|